Horwich T B, Fonarow G C, Hamilton M A, MacLellan W R, Woo M A, Tillisch J H
Department of Medicine, University of California at Los Angeles Medical Center, Los Angeles, California, USA.
J Am Coll Cardiol. 2001 Sep;38(3):789-95. doi: 10.1016/s0735-1097(01)01448-6.
The study aimed to evaluate the role of obesity in the prognosis of patients with heart failure (HF).
Previous reports link obesity to the development of HF. However, the impact of obesity in patients with established HF has not been studied.
We analyzed 1,203 patients with advanced HF followed in a comprehensive HF management program. The patients were subclassified into categories of body mass index (BMI) defined as: underweight BMI <20.7 (n = 164), recommended BMI 20.7 to 27.7 (n = 692), overweight BMI 27.8 to 31 (n = 168) and obese BMI >31 (n = 179). This sample size allows the detection of small effects (0.02), with a power of 0.80 and an alpha level of 0.05 for comparing one-year survival between BMI groups.
The four BMI groups had similar profiles in terms of ejection fraction (mean 0.22), sodium, creatinine and smoking. The obese and overweight groups had significantly higher rates of hypertension and diabetes, as well as higher levels of cholesterol, triglycerides and low density lipoprotein cholesterol. The four BMI groups had similar survival rates. Ejection fraction, HF etiology and angiotensin-converting enzyme inhibitor use predicted survival on univariate analysis (p < 0.01), although BMI did not. On multivariate analysis, cardiopulmonary exercise tests, pulmonary capillary wedge pressure and serum sodium were strong predictors of survival (p < 0.05). Higher BMI was not a risk factor for increased mortality, but was associated with a trend toward improved survival.
In a large cohort of patients with advanced HF of multiple etiologies, obesity is not associated with increased mortality and may confer a more favorable prognosis. Further studies need to delineate whether weight loss promotion in medically optimized patients with HF is a worthwhile therapeutic goal.
本研究旨在评估肥胖在心力衰竭(HF)患者预后中的作用。
既往报告将肥胖与HF的发生联系起来。然而,肥胖对已确诊HF患者的影响尚未得到研究。
我们分析了在一个综合性HF管理项目中随访的1203例晚期HF患者。患者根据体重指数(BMI)分为以下几类:体重过轻,BMI<20.7(n = 164);推荐BMI,20.7至27.7(n = 692);超重,BMI 27.8至31(n = 168);肥胖,BMI>31(n = 179)。该样本量能够检测到微小效应(0.02),检验效能为0.80,α水平为0.05,用于比较BMI组之间的一年生存率。
四个BMI组在射血分数(平均0.22)、钠、肌酐和吸烟方面具有相似的特征。肥胖组和超重组的高血压和糖尿病发生率显著更高,胆固醇、甘油三酯和低密度脂蛋白胆固醇水平也更高。四个BMI组的生存率相似。在单因素分析中,射血分数、HF病因和血管紧张素转换酶抑制剂的使用可预测生存率(p<0.01),尽管BMI不能。在多因素分析中,心肺运动试验、肺毛细血管楔压和血清钠是生存率的强预测因素(p<0.05)。较高的BMI不是死亡率增加的危险因素,但与生存率改善的趋势相关。
在一大群病因多样的晚期HF患者中,肥胖与死亡率增加无关,可能具有更有利的预后。需要进一步研究来确定在药物治疗优化的HF患者中促进体重减轻是否是一个值得追求的治疗目标。